Chondroblastoma's Lung Metastases Treated with Denosumab in Pediatric Patient

Marco Focaccia, Marco Gambarotti, Rossella Hakim, Anna Paioli, Marilena Cesari, Benedetta Spazzoli, Paolo Spinnato, Davide Donati, Michele Rocca, Alessandra Longhi

Research output: Contribution to journalArticlepeer-review

Abstract

Chondroblastoma is a rare benign chondrogenic tumor that occurs in skeletally immature patients between ages 10 and 20 years old. In literature are reported few cases of lung metastases, mainly occurred after surgery or local recurrences. There is no evidence on the pathogenesis of lung metastasis, as well as pulmonary disease course. Few treatments for metastases with aggressive behavior were based on chemotherapy regimen employed in other sarcoma with no results or not satisfying ones. Denosumab is approved for treatment of giant cell tumors and it is under investigation for other giant cell-rich bone tumors. Here, we report a case of a 16-year-old male chondroblastoma of the left humerus with bilateral lung metastases at presentation and progressing during follow-up, treated with denosumab for almost 2 years. We confirm that denosumab treatment can be effective in controlling chondroblastoma metastasis and it has been a safe procedure in an adolescent patient.

Original languageEnglish
JournalCancer Research and Treatment
DOIs
Publication statusPublished - 2021

Keywords

  • Chemotherapy
  • Chondroblastoma
  • Denosumab
  • Lung
  • Metastasis
  • Pediatric

Fingerprint Dive into the research topics of 'Chondroblastoma's Lung Metastases Treated with Denosumab in Pediatric Patient'. Together they form a unique fingerprint.

Cite this